What is the difference between Doxycycline Monohydrate and Minocycline Hydrochloride Extended-Release?

Doxycycline Monohydrate and Minocycline Hydrochloride Extended-Release are both Tetracycline Antibiotics, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Is Doxycycline Monohydrate the same as Emrosi?

No. Doxycycline Monohydrate (Doxycycline Monohydrate) and Emrosi (Minocycline Hydrochloride Extended-Release) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, Doxycycline Monohydrate or Minocycline Hydrochloride Extended-Release?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from Doxycycline Monohydrate to Minocycline Hydrochloride Extended-Release?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release

Compare Doxycycline Monohydrate (Doxycycline Monohydrate) and Minocycline Hydrochloride Extended-Release (Emrosi), clinical data, side effects, and patient experiences.

Doxycycline Monohydrate

Doxycycline Monohydrate, Vibramycin, Efracea · Tetracycline Antibiotic

How it works

Tetracycline Antibiotic agent

Approved for

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs

they should be considered in selecting or modifying antibacterial therapy. In the absence of such data

local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever

typhus fever and the typhus group

OralTablet

Minocycline Hydrochloride Extended-Release

Emrosi · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown.

Approved for

use EMROSI only as indicated. ( 1 )

OralTablet

Quick Comparison

Doxycycline MonohydrateMinocycline Hydrochloride Extended-Release

Drug Class

Tetracycline Antibiotic

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Doxycycline Monohydrate

Drug Not Working

1-10%

Nausea

1-10%

Fatigue

1-10%

Rash

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Vomiting

1-10%

Minocycline Hydrochloride Extended-Release

Drug Not Working

>10%

Nausea

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

FDA Warnings

Doxycycline Monohydrate

WARNINGS The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown)
Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline capsules, and may range in severity from mild diarrhea to fatal colitis
Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH

Minocycline Hydrochloride Extended-Release

5 WARNINGS AND PRECAUTIONS Serious Skin/Hypersensitivity Reactions: Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome
1 Hypersensitivity Reaction and Serious Skin Reactions Cases of anaphylaxis, serious skin reactions (e
In some cases, death has been reported
Advise the patient of the potential risk to the fetus if EMROSI is used during the second or third trimester of pregnancy [see Use in Specific Populations (8

Clinical Trial Data

No head-to-head clinical studies found for Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release.

Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release: What You Should Know

Key Differences

Both Doxycycline Monohydrate and Minocycline Hydrochloride Extended-Release belong to the Tetracycline Antibiotic class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

Doxycycline Monohydrate carries 4 FDA warnings. Minocycline Hydrochloride Extended-Release carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Doxycycline Monohydrate vs Tigecycline→Doxycycline Monohydrate vs Omadacycline→Doxycycline Monohydrate vs Tetracycline Hydrochloride→Doxycycline vs Doxycycline Monohydrate→Doxycycline Hyclate vs Doxycycline Monohydrate→Doxycycline Monohydrate vs Minocycline Hydrochloride→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Doxycycline Monohydrate: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Minocycline Hydrochloride Extended-Release: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release

Compare Doxycycline Monohydrate (Doxycycline Monohydrate) and Minocycline Hydrochloride Extended-Release (Emrosi), clinical data, side effects, and patient experiences.

Doxycycline Monohydrate

Doxycycline Monohydrate, Vibramycin, Efracea · Tetracycline Antibiotic

How it works

Tetracycline Antibiotic agent

Approved for

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs

they should be considered in selecting or modifying antibacterial therapy. In the absence of such data

local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever

typhus fever and the typhus group

OralTablet

Minocycline Hydrochloride Extended-Release

Emrosi · Tetracycline Antibiotic

How it works

12.1 Mechanism of Action The mechanism of action of EMROSI for the treatment of rosacea is unknown.

Approved for

use EMROSI only as indicated. ( 1 )

OralTablet

Quick Comparison

Doxycycline MonohydrateMinocycline Hydrochloride Extended-Release

Drug Class

Tetracycline Antibiotic

Route

Oral

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Doxycycline Monohydrate

Drug Not Working

1-10%

Nausea

1-10%

Fatigue

1-10%

Rash

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Vomiting

1-10%

Minocycline Hydrochloride Extended-Release

Drug Not Working

>10%

Nausea

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Headache

1-10%

Condition Worsened

1-10%

Diarrhea

0.1-1%

FDA Warnings

Doxycycline Monohydrate

WARNINGS The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown)
Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline capsules, and may range in severity from mild diarrhea to fatal colitis
Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH

Minocycline Hydrochloride Extended-Release

5 WARNINGS AND PRECAUTIONS Serious Skin/Hypersensitivity Reactions: Minocycline has been associated with anaphylaxis, serious skin reactions, erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome
1 Hypersensitivity Reaction and Serious Skin Reactions Cases of anaphylaxis, serious skin reactions (e
In some cases, death has been reported
Advise the patient of the potential risk to the fetus if EMROSI is used during the second or third trimester of pregnancy [see Use in Specific Populations (8

Clinical Trial Data

No head-to-head clinical studies found for Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release.

Doxycycline Monohydrate vs Minocycline Hydrochloride Extended-Release: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Doxycycline Monohydrate: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Minocycline Hydrochloride Extended-Release: DailyMed label · FAERS adverse events · ClinicalTrials.gov